Evidence map›Paper›PMID 40563049›Full record

ArticleInternational journal of clinical oncology2025

Multimodal treatments for patients with locally advanced synchronous esophageal and head and neck cancer.

Satoshi Suzuki, Tomoya Yokota, Akifumi Notsu, Satoshi Hamauchi, Kunihiro Fushiki, Kotoe Oshima, Akihiro Ohba, Takeshi Kawakami, Takahiro Tsushima, Hirofumi Yasui and 6 more

Erratum issuedAbstract read
PubMed Publisher
In one paragraph

Article in International journal of clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors.

Satoshi SuzukiDepartment of Head and Neck Medical Oncology, Division of Gastrointestinal Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi, Sunto-Gun, Shizuoka, 411-8777, Japan.
Tomoya YokotaDepartment of Head and Neck Medical Oncology, Division of Gastrointestinal Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi, Sunto-Gun, Shizuoka, 411-8777, Japan. t.yokota@scchr.jp.ORCID http://orcid.org/0000-0001-7327-7949
Akifumi NotsuClinical Research Center, Shizuoka Cancer Center, Shizuoka, Japan.
Satoshi HamauchiDepartment of Head and Neck Medical Oncology, Division of Gastrointestinal Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi, Sunto-Gun, Shizuoka, 411-8777, Japan.
Kunihiro FushikiDepartment of Head and Neck Medical Oncology, Division of Gastrointestinal Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi, Sunto-Gun, Shizuoka, 411-8777, Japan.
Kotoe OshimaDepartment of Head and Neck Medical Oncology, Division of Gastrointestinal Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi, Sunto-Gun, Shizuoka, 411-8777, Japan.
Akihiro OhbaDepartment of Head and Neck Medical Oncology, Division of Gastrointestinal Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi, Sunto-Gun, Shizuoka, 411-8777, Japan.
Takeshi KawakamiDepartment of Head and Neck Medical Oncology, Division of Gastrointestinal Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi, Sunto-Gun, Shizuoka, 411-8777, Japan.
Takahiro TsushimaDepartment of Head and Neck Medical Oncology, Division of Gastrointestinal Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi, Sunto-Gun, Shizuoka, 411-8777, Japan.
Hirofumi YasuiDepartment of Head and Neck Medical Oncology, Division of Gastrointestinal Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi, Sunto-Gun, Shizuoka, 411-8777, Japan.
Kentaro YamazakiDepartment of Head and Neck Medical Oncology, Division of Gastrointestinal Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi, Sunto-Gun, Shizuoka, 411-8777, Japan.
Yusuke OnozawaDivision of Medical Oncology, Shizuoka Cancer Center, Shizuoka, Japan.
Takashi MukaigawaDivision of Head and Neck Surgery, Shizuoka Cancer Center, Shizuoka, Japan.
Yasuhiro TsubosaDivision of Esophageal Surgery, Shizuoka Cancer Center, Shizuoka, Japan.
Hirofumi OgawaDivision of Radiation and Proton Therapy Center, Shizuoka Cancer Center, Shizuoka, Japan.
Tsuyoshi OnoeDivision of Radiation and Proton Therapy Center, Shizuoka Cancer Center, Shizuoka, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHead and neck squamous cell carcinoma (HNSCC) and esophageal squamous cell carcinoma (ESCC) sometimes synchronously exist. In this study, we aim to investigate survival outcome and late adverse events (AEs) in patients with locally advanced synchronous ESCC and HNSCC (LA-SEHNC).

methodsWe retrospectively analyzed consecutive patients with LA-SEHNC who underwent curative-intent surgery or chemoradiotherapy (CRT) for HNSCC and ESCC between 2007 and 2024. Patients were classified into 3 groups: group A, surgery for both HNSCC and ESCC; group B, CRT for both HNSCC and ESCC; group C, CRT for either HNSCC or ESCC.

resultsForty-two patients with LA-SEHNC were identified, consisting of 7 in group A, 28 in B, and 7 in C. There were no differences in overall survival and recurrence-free survival among groups. Late AEs occurred more frequently in group B and C than A, including stenosis (51.9%/57.1% vs 0%; p = 0.04), dysphagia (59.3%/42.9% vs 0% vs.; p = 0.02), and xerostomia (74.1%/57.1% vs 14.3%; p = 0.01). The median duration of feeding tube dependency was significantly longer in group B than A (80 days vs 0 day; p < 0.01). PS ≥ 1 and irradiation at head and neck region was significantly associated with long-term feeding tube dependency (odds ratio [OR] 9.10, p = 0.005, OR 7.71e + 7, p = 0.024, respectively).

conclusionAlthough no significant difference in survival was found among patients with LA-SEHNC regardless of treatment modalities, the use of radiotherapy may be associated with increased late AEs.

Indexed as

Esophageal NeoplasmsEsophageal Squamous Cell CarcinomaHead and Neck NeoplasmsNeoplasms, Multiple PrimarySquamous Cell Carcinoma of Head and NeckAdultAgedChemoradiotherapyCombined Modality TherapyFemaleHumansMaleMiddle AgedRetrospective StudiesChemoradiotherapyEsophageal cancerFeeding tube dependencyHead and neck cancerLate adverse eventsSurgerySynchronous cancer

Identifiers

PMID40563049

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.